The Wegovy weight loss plan: what the decision really involves

Decision 1: is Wegovy's mechanism right for how your appetite works?

Semaglutide acts on GLP-1 receptors in the gut and brain. In practical terms, meals feel satisfying sooner, hunger between meals quietens, and the drive to snack late in the evening tends to ease. For people whose weight is driven largely by appetite volume and persistent hunger, this mechanism fits well. For those whose eating is primarily emotional or habitual rather than hunger-driven, the medicine reduces one signal but not others, and that distinction matters when you are deciding whether a Wegovy weight loss plan is genuinely the right tool.

The full semaglutide profile covers the receptor mechanism in more detail. The short version: Wegovy does not suppress willpower; it adjusts a biological signal that, for many people, has been running louder than it should. That reframing is clinically important and worth sitting with before you start.

Side effects are also part of this decision. Nausea, loose stools, constipation and indigestion are the most commonly reported effects, particularly in the first weeks of a new dose. They tend to be mild to moderate and settle as your system adjusts. Fatigue, burping and headache appear less often. The dose escalation schedule (starting low and titrating slowly under prescriber supervision) exists specifically to manage tolerability. You will not be jumping straight to the maintenance dose on day one.

Decision 2: how long are you planning to commit, and what does the evidence say about that window?

This is where many people's expectations and the clinical reality diverge. Wegovy is not a short course. The STEP 1 trial ran for 68 weeks, and the weight reductions recorded (an average of around 15% of starting body weight) reflected sustained treatment throughout that period, as published in the New England Journal of Medicine. When treatment stopped in subsequent trials, a substantial proportion of weight returned within a year, which tells you something important: the medicine is managing a chronic condition, not curing it.

NICE's guidance on semaglutide (TA875) caps NHS use at a maximum of two years within a specialist service. Private use under a licensed prescriber is not bound by that ceiling, but the clinical logic holds: weight management is long-term work, and a Wegovy plan should be designed with that in mind from the start. Your prescriber will review progress at each stage; if the medicine is not producing meaningful results, continuing is not automatic.

Payday timing, a two-week holiday, a planned surgery, all of these interact with a treatment schedule that runs in four-week pen cycles. Planning around them early, rather than discovering a gap mid-titration, makes a difference. It is the kind of practical detail a prescriber can help you map out.

Decision 3: NHS route or private, and what each actually involves

NHS access to Wegovy runs through specialist weight management services under NICE TA875, with BMI and comorbidity thresholds and, commonly, meaningful waiting times. Private prescribing through a regulated weight loss service removes the waiting list but requires a clinical assessment all the same, the prescription-only status does not change. A GPhC-registered prescriber reviews your medical history, current medicines, and suitability before anything is dispensed.

The cost picture for private treatment is covered separately on the Wegovy private treatment page, including what a legitimate price includes and what to be cautious about. The short version: a single transparent price should cover consultation, prescription, the medicine, and aftercare, not just the pen.

Verifying any online pharmacy before you use it takes thirty seconds on the GPhC pharmacy register. The MHRA has warned repeatedly about counterfeit semaglutide pens circulating online, some containing insulin. If a seller is offering semaglutide without a clinical assessment, that is a serious red flag, not a shortcut worth taking.

Decision 4: what does a well-structured plan actually look like day to day?

A weight Wegovy plan has several moving parts beyond the injection itself. Diet quality matters: with appetite reduced, total food volume drops, and getting adequate protein, fibre and micronutrients from a smaller intake requires some thought. The NHS's healthy weight guidance provides a practical starting point, and your prescriber or a dietitian can help you build on it.

Physical activity plays a supporting role, both for metabolic health and for preserving lean muscle mass during weight loss. The intensity does not need to be dramatic; consistent movement matters more than any single session. Hydration is worth flagging too, GI side effects in the early weeks can increase fluid loss, and staying well-hydrated reduces the risk of them becoming problematic.

Clinical re-review at each repeat is not optional box-ticking. It is the mechanism that catches problems early, adjusts the plan if something is not working, and ensures the treatment remains appropriate as your situation changes. At nume, every repeat order is reviewed by a GPhC-registered prescriber before it is dispensed, not once at the start and then left to run. If you have questions about whether this plan fits your circumstances, you can read more about semaglutide weight loss or start a free consultation as the practical next step.